Satellos Bioscience (TSX:MSCL) Additional Paid-In Capital : C$6.77 Mil(As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Additional Paid-In Capital?

Satellos Bioscience's quarterly additional paid-in capital increased from Sep. 2023 (C$3.99 Mil) to Dec. 2023 (C$5.02 Mil) and increased from Dec. 2023 (C$5.02 Mil) to Mar. 2024 (C$6.77 Mil).

Satellos Bioscience's annual additional paid-in capital increased from Dec. 2021 (C$1.24 Mil) to Dec. 2022 (C$3.69 Mil) and increased from Dec. 2022 (C$3.69 Mil) to Dec. 2023 (C$5.02 Mil).

Satellos Bioscience Additional Paid-In Capital Historical Data

The historical data trend for Satellos Bioscience's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Additional Paid-In Capital Chart

Satellos Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

0.25

1.24

3.69

5.02

Satellos Bioscience Quarterly Data
	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial										2.88	3.25	3.99	5.02	6.77

Satellos Bioscience Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Satellos Bioscience Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Satellos Bioscience (TSX:MSCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

MSCLF:USA 0IT:Germany

Address

65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5

Website

https://www.satellos.com

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines